BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16918414)

  • 21. [Progress in the study of targeted drug delivery systems for cancer stem cells].
    Qiao MX; Zhang XJ; Shuang BA; Hu HY; Zhao XL; Chen DW
    Yao Xue Xue Bao; 2013 Apr; 48(4):477-83. PubMed ID: 23833932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoxia-targeted drug delivery.
    Sharma A; Arambula JF; Koo S; Kumar R; Singh H; Sessler JL; Kim JS
    Chem Soc Rev; 2019 Feb; 48(3):771-813. PubMed ID: 30575832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PI3K/Akt signalling pathway and cancer.
    Fresno Vara JA; Casado E; de Castro J; Cejas P; Belda-Iniesta C; González-Barón M
    Cancer Treat Rev; 2004 Apr; 30(2):193-204. PubMed ID: 15023437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
    Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
    Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting survivin in cancer: the cell-signalling perspective.
    Kanwar JR; Kamalapuram SK; Kanwar RK
    Drug Discov Today; 2011 Jun; 16(11-12):485-94. PubMed ID: 21511051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
    Kim BH; Yi EH; Ye SK
    Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
    Meads MB; Hazlehurst LA; Dalton WS
    Clin Cancer Res; 2008 May; 14(9):2519-26. PubMed ID: 18451212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells.
    Croix BS; Rak JW; Kapitain S; Sheehan C; Graham CH; Kerbel RS
    J Natl Cancer Inst; 1996 Sep; 88(18):1285-96. PubMed ID: 8797768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies to Strike Survival Networks in Cancer.
    Pennati M; Cimino-Reale G; Gatti L; Cassinelli G
    Crit Rev Oncog; 2016; 21(3-4):269-308. PubMed ID: 27915976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism.
    Hakomori S
    Cancer Res; 1996 Dec; 56(23):5309-18. PubMed ID: 8968075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of adhesion molecules in cancer and targeted therapy.
    Fan C; Xiong F; Zhang S; Gong Z; Liao Q; Li G; Guo C; Xiong W; Huang H; Zeng Z
    Sci China Life Sci; 2024 May; 67(5):940-957. PubMed ID: 38212458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adhesion molecules as targets for cancer therapy.
    Huang YW; Baluna R; Vitetta ES
    Histol Histopathol; 1997 Apr; 12(2):467-77. PubMed ID: 9151136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug penetration in solid tumours.
    Minchinton AI; Tannock IF
    Nat Rev Cancer; 2006 Aug; 6(8):583-92. PubMed ID: 16862189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer.
    Vallette FM; Olivier C; Lézot F; Oliver L; Cochonneau D; Lalier L; Cartron PF; Heymann D
    Biochem Pharmacol; 2019 Apr; 162():169-176. PubMed ID: 30414937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the TGFβ pathway for cancer therapy.
    Neuzillet C; Tijeras-Raballand A; Cohen R; Cros J; Faivre S; Raymond E; de Gramont A
    Pharmacol Ther; 2015 Mar; 147():22-31. PubMed ID: 25444759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
    Wang K; Baldwin GS; Nikfarjam M; He H
    World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticle approaches to combating drug resistance.
    Moon JH; Moxley JW; Zhang P; Cui H
    Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.